EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast

Yuko Takano, Kazuyuki Mizuno, Madoka Iwase, Sachi Morita, Nao Torii, Toyone Kikumori, Yuichi Ando

Breast Cancer · 2025

DOI: 10.1007/s12282-025-01706-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer, 2025. Verfasst von Yuko Takano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 65 Tsurumai-Cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan. takano.yuko.…. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma, Lobular, Biomarkers, Tumor, Carcinoma, Ductal, Breast. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nagoya University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High tumor mutational burden (TMB-H) is an established biomarker for a favorable response to immune checkpoint inhibitors. However, tumor mutational burden (TMB) in invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) has not been sufficiently investigated.

Methods

We collected data of patients with ILC or IDC from the Center for Cancer Genomics and Advanced Therapeutics database between June 2019 and August 2023. Furthermore, we examined the clinicopathological factors and TMB status.

Results

Patients with ILC (n = 170) had a median TMB score of 4.00 mut/Mb (interquartile range, 2.00–7.14 mut/Mb), whereas those with IDC (n = 2598) had a score of 3.90 mut/Mb (2.00–6.00 mut/Mb). TMB-H was more common in patients with ILC than in those with IDC (18.2% vs. 10.1%, P < 0.001), particularly in the ER+ /HER2− subtype. Multivariate analysis revealed that the pathological diagnosis of ILC ( P = 0.006), tissue samples collected from metastatic sites ( P < 0.001), and older age (50 years, P < 0.001) were independent factors for TMB-H.

Conclusions

Patients with ILC were more likely to have TMB-H than those with IDC. The findings of this study would be invaluable in selecting treatment strategies for patients with ILC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCarcinoma, LobularBiomarkers, TumorCarcinoma, Ductal, BreastHumansFemaleMiddle AgedMutationAgedAdultTumor BurdenPrognosisRetrospective Studies

Stichwörter der Autor:innen

High tumor mutational burdenInvasive ductal carcinomaInvasive lobular carcinoma

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 65 Tsurumai-Cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan. takano.yuko.h3@f.mail.nagoya-u.ac.jp.
  • Department of Breast and Endocrine Surgery, Nagoya University Hospital, 65 Tsurumai-Cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan. takano.yuko.h3@f.mail.nagoya-u.ac.jp.
  • Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 65 Tsurumai-Cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan.
  • Department of Breast and Endocrine Surgery, Nagoya University Hospital, 65 Tsurumai-Cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan.

Förderung

  • Nagoya University

Zitieren

APA

Takano, Y., Mizuno, K., Iwase, M., Morita, S., Torii, N., Kikumori, T., & Ando, Y. (2025). Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast. Breast Cancer. https://doi.org/10.1007/s12282-025-01706-6

Vancouver

Takano Y, Mizuno K, Iwase M, Morita S, Torii N, Kikumori T, et al. Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast. Breast Cancer. 2025. doi:10.1007/s12282-025-01706-6

BibTeX
@article{Takano2025,
  author = {Takano, Yuko and Mizuno, Kazuyuki and Iwase, Madoka and Morita, Sachi and Torii, Nao and Kikumori, Toyone and Ando, Yuichi},
  title = {Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast},
  journal = {Breast Cancer},
  year = {2025},
  doi = {10.1007/s12282-025-01706-6}
}
Kostenlos starten →